Pros and Cons of Fosamprenavir
Pros and Cons of Fosamprenavir
Pablo Barreiro
Department of Infectious Diseases, Hospital Carlos III-La Paz University Hospital. Madrid, Spain
*Correspondence: Pablo Barreiro, Email not available
Abstract
Two new protease inhibitors have been recentlyapproved by the FDA: atazanavir andfosamprenavir. Another one, tipranavir, willmost likely enter the market within the nextfew months. What can we expect from thesenew products? Data presented on fosamprenavirat the 9th European Conference onAIDS, which took place last October in Warsaw,Poland, provided new light on the mainfeatures of the drug.
